Skip to main content
. 2017 Feb 9;64(5):621–628. doi: 10.1093/cid/ciw833

Table 1.

Characteristics and Bi-and Multivariate Analyses of the Study Cohort

Characteristic LTNP-C (n = 100) Non-LTNP-C (n = 40) P; OR (95% CI) P; OR (95% CI)
Unadjusted Adjusted
Sex (male) 69 (69) 20 (50) .037; 2.226 (1.051–4.716) .040; 2.467 (1.040–5.852)
Age at HIV diagnosis (years) 26.2 [22.1–31.8] 29.9 [25.0–34.1] .038; .950 (.904–.997) .102; .957 (.908–1.009)
Interferon-lambda 4 TT/TT genotypea 42 (44) 26 (65) .029; .427 (.198–.918) .036; .401 (.171–.942)
HLA-B*27b,c 18 (18) 7 (18) .982; .989 (.375–2.607)
HLA-B*57b,c 29 (29) 5 (13) .054; 2.770 (.981–7.824) .044; 3.056 (1.029–9.069)
HLA-B*35b,c 10 (10) 7 (18) .194; .498 (.174–1.426)
HLA-B*08b,c 5 (5) 2 (5) .964; .962 (.178–5.188)

Qualitative data are number (%) of individuals and quantitative data are median (interquartile range). Significant values are shown in bold.

Abbreviations: CI, confidence interval; HIV, human immunodeficiency virus; HLA, human leukocyte antigen; LTNP-C, long-term nonprogressor HIV-1 controller; OR, odds ratio.

aData were available for 135 patients (95 LTNP-Cs and 40 non-LTNP-Cs).

bData were available for 133 patients (96 LTNP-Cs and 37 non-LTNP-Cs).

cDominant model was applied. There were no homozygous patients for HLA-B*57.